From presenting Phase 1 data at #ESMOGI24 → @NatureMedicine publication in 2025 → seeing positive Phase 3 results from G-HOPE-001 in CLDN18.2 positive 3L+ G/GEJA presented by @KoheiShitara at #ESMO26!
Wonderful to have been part of the development journey of arcotatug tavatecan (IBI343), a CLDN18.2-targeting ADC!
📊 OS HR 0.57 (10.2 vs 6.9 mo)
📊 PFS HR 0.45 (7.1 vs 3.1 mo)
💊 Grade ≥3 treatment-related AEs: 47.4% vs 55.9%; dose reductions: 17.8% vs 35.1% compared with chemotherapy.
Congratulations to all investigators and the Innovent & Takeda teams!
Looking forward to exploring rational combinations to further improve patient outcomes!
#ADC #GastricCancer @myESMO @OncoAlert @oncodaily
1022 浏览 · 19 赞 · 5 转发 · 1 回复
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.org- Sumanta K. Pal, MD, FASCO@montypal
@JiaJennyLiu @NatureMedicine @KoheiShitara What a terrific continuum - congratulations!
来源：Jia (Jenny) Liu MD PhD · x.com